67
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Determining cell-type abundance and expression from bulk tissues with digital cytometry

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Single-cell RNA-seq (scRNA-seq) has emerged as a powerful technique for characterizing cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be applied to fixed specimens collected as part of routine clinical care. We previously developed an approach for digital cytometry, called CIBERSORT, that enables estimation of cell type abundances from bulk tissue transcriptomes. We now introduce CIBERSORTx, a machine learning method that extends this framework to infer cell-type-specific gene expression profiles without physical cell isolation. By minimizing platform-specific variation, CIBERSORTx also allows the use of scRNA-seq data for large-scale tissue dissection. We evaluated the utility of CIBERSORTx in multiple tumor types, including melanoma, where single-cell reference profiles were used to dissect bulk clinical specimens, revealing cell type-specific phenotypic states linked to distinct driver mutations and response to immune checkpoint blockade. We anticipate that digital cytometry will augment single-cell profiling efforts, enabling cost-effective, high-throughput tissue characterization without the need for antibodies, disaggregation, or viable cells.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

          Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here, we have overcome this problem by applying blind source separation to a diverse collection of PDAC gene expression microarray data, which includes primary, metastatic, and normal samples. By digitally separating tumor, stroma, and normal gene expression, we have identified and validated two tumor-specific subtypes including a “basal-like” subtype which has worse outcome, and is molecularly similar to basal tumors in bladder and breast cancer. Furthermore, we define “normal” and “activated” stromal subtypes which are independently prognostic. Our results provide new insight into the molecular composition of PDAC which may be used to tailor therapies or provide decision support in a clinical setting where the choice and timing of therapies is critical.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring

            T. Golub (1999)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

              The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations that lead to deregulation of cell signalling pathways central to the control of cell growth and cell fate. The ability to define cancer subtypes, recurrence of disease and response to specific therapies using DNA microarray-based gene expression signatures has been demonstrated in multiple studies. Various studies have also demonstrated the potential for using gene expression profiles for the analysis of oncogenic pathways. Here we show that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways. When evaluated in several large collections of human cancers, these gene expression signatures identify patterns of pathway deregulation in tumours and clinically relevant associations with disease outcomes. Combining signature-based predictions across several pathways identifies coordinated patterns of pathway deregulation that distinguish between specific cancers and tumour subtypes. Clustering tumours based on pathway signatures further defines prognosis in respective patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. Predictions of pathway deregulation in cancer cell lines are also shown to predict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics.
                Bookmark

                Author and article information

                Journal
                9604648
                20305
                Nat Biotechnol
                Nat. Biotechnol.
                Nature biotechnology
                1087-0156
                1546-1696
                18 April 2019
                06 May 2019
                July 2019
                06 November 2019
                : 37
                : 7
                : 773-782
                Affiliations
                [1 ]Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
                [2 ]Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
                [3 ]Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California, USA.
                [4 ]Department of Informatics, University of Oslo, Oslo, Norway.
                [5 ]Center for Cancer Systems Biology, Stanford University, Stanford, California, USA.
                [6 ]Stanford Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, California, USA.
                [7 ]Department of Radiation Oncology, Stanford University, Stanford, California, USA.
                [8 ]Stanford Cancer Institute, Stanford University, Stanford, California, USA.
                [9 ]Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California, USA.
                Author notes
                [# ] Correspondence should be addressed to: Aaron M. Newman, Ph.D., Institute for Stem Cell Biology & Regenerative Medicine, and Department of Biomedical Data Science, amnewman@ 123456stanford.edu , Tel: 650-724-7270 and Ash A. Alizadeh, M.D./Ph.D., Division of Oncology, Department of Medicine, Stanford Cancer Institute, and Institute for Stem Cell Biology & Regenerative Medicine, arasha@ 123456stanford.edu , Tel: 650-725-0120

                Author Contributions

                A.M.N. and A.A.A. conceived of CIBERSORTx, developed strategies for related experiments, and wrote the paper with input from C.L.L., C.B.S., A.J.G., M.S.E., and M.D. A.M.N. developed and implemented CIBERSORTx and analyzed the data. C.L.L. and C.B.S. implemented web infrastructure. C.B.S. assisted with CIBERSORTx software development and validation experiments. A.J.G. assisted in the development of CIBERSORTx. A.A.C. and M.S.K. performed flow cytometry and single-cell profiling. F.S. performed targeted DNA sequencing of FL tumor specimens. B.A.L. assisted with validation studies. D.S. assisted with data acquisition. M.D. assisted in the collection and expression profiling of patient specimens. All authors commented on the manuscript at all stages.

                Article
                NIHMS1525543
                10.1038/s41587-019-0114-2
                6610714
                31061481
                5090bd46-3a18-47dc-8129-e6a1b3148bcf

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Biotechnology
                Biotechnology

                Comments

                Comment on this article